Japan’s Shionogi Starts COVID-19 Vaccine Trial Among Children

Health News

TOKYO (Reuters) – Japan’s Shionogi & Co Ltd said on Tuesday it started a clinical trial of its COVID-19 vaccine candidate among children aged 5 to 11.

The phase I/II/III clinical trial of the recombinant protein-based vaccine known as S-268019 will be carried out among 48 children in Japan, the company said in a release.

The vaccine has not yet been approved by Japanese regulators for use among adults.

(Reporting by Rocky Swift; Editing by Christopher Cushing)

Source: Read Full Article

Related posts:
  1. Covid vaccine: What is the Sinovac vaccine? How effective is China’s coronavirus vaccine?
  2. Miniaturized models of neuron-muscle interactions give insight in ALS
  3. Researchers find that combining melatonin with vancomycin reduces kidney failure
  4. Statins side effects: ‘Pink-red blotches’ considered serious side effect – ‘call a doctor’
  5. Struggling to calm anxiety before bed? Here’s how ‘vagus nerve icing’ could help